Formulation, Development & Delivery In-Depth Focus 2019
Included in this in-depth focus are features on recombinant albumin as a versatile stabiliser and how nanobots will evolve as an effective drug delivery technique.
List view / Grid view
Articles
Bioprocessing & Bioproduction In-Depth Focus 2019
Within this in-depth focus are articles exploring the potential of gene therapies and manufacturing viral vectors as well as a discussion on recent M&As within the biopharmaceutical industry.
Manufacturing, Packaging & Logistics In-Depth Focus 2019
In this in-depth focus are articles on the latest innovations in pharmaceutical packaging design and how to comply with the new EU Medical Device Regulations (MDR) for product labelling.
The real reason you’re struggling to stay compliant
For companies in highly regulated industries, compliance is second only to survival as a business. Yet why do so many companies struggle with compliance? Dr Rebecca Godfrey explores this issue and provides practical steps that companies can take to ensure best practice.
ICH M9: biopharmaceutics classification system-based biowaivers
ICH M9 biopharmaceutics classification system-based biowaivers1 is currently at step 2b and feedback from interested parties is being evaluated.2 This guideline should reach the implementation stage (step 4) during 2020. However, industry still has concerns relating to several key areas of the guidance. Here, Dave Elder summarises these ICH M9…
Medical devices: recent developments and the potential impact of Brexit
The current regulatory system for medical devices in the UK, as an EU member state, is complex enough without the uncertainties surrounding Brexit. In this article, legal advisor Paul Ranson reviews the current and forthcoming regimes and how Brexit may impact manufacturers and regulators working in this space.
European Pharmaceutical Review Issue 6 2019
In this issue are articles that explore the impact of M&As within the life science industry, discuss the security trends for medicinal packaging and investigate genotoxic impurities within pharmaceutical products. Also included are features on nanobot drug delivery systems and Raman as an effective analytical approach.
Medical cannabis: face-to-face with Dr Zeid Mohamedali
Dr Mohamedali discusses Canada's stance on medical cannabis and breaks down some misconceptions surrounding cannabinoids, as well as exploring the future for the pharmaceutical ingredient.
The global cannabinoid pharmaceutical industry
Cannabinoids are of growing interest in the pharmaceutical industry. Mark Tucker explains how this class of compounds is viewed across the world and why regulations surrounding them hinder their progress, yet remain necessary.
Optimising artificial intelligence in the pharmaceutical industry
Artificial intelligence can be applied to almost every part of the pharma industry. Christopher Rafter discusses its many uses and how the adoption of machine learning will increase in the future.
Medical cannabis: face-to-face with Dr Michael Platt
Dr Platt describes how medical cannabis can be used to treat conditions such as pain, his area of expertise. He also explains how perception has influenced the acceptance of cannabinoids.
Safe as houses: the market impact of safety syringes in hospital and home drug administration
As the demand for safety-syringes increases, the market for pre-filled safety-engineered devices will increase. This article outlines the main drivers behind this growth.
Medical cannabis: face-to-face with Dr Mikael Sodergren
Dr Sodergren explores the uses of medical cannabis, describing its applications. He also discusses the future of cannabinoid research in the short- and long-term.
The Brexit test: protecting pharmaceutical quality standards through better analysis
In the wake of Brexit, the pharma industry will need to respond to a new regulatory landscape. Peter Morgan discusses how businesses have to prepare for the oncoming political changes, all whist retaining high pharmaceutical product quality.
Combatting drug shortages in the EU: new guidance
New guidance for marketing authorisation holders has been released by the EMA to reduce the impact of drug shortages in the EU. Maurits Lugard and Anna-Shari Melin at Sidley Austin discuss the document and highlight its main points.
